Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study
Uçan et al., Research Square, doi:10.21203/ (Preprint)
Uçan et al., Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational.., Research Square, doi:10.21203/ (Preprint)
Feb 2021   Source   PDF  
  All Studies   Meta
Retrospective 144 COVID-19 patients in Turkey, one group receiving FPV after a mean of 4.7 days, a second group after a mean of 8.6 days, and all groups receiving HCQ. No improvement in clinical outcomes was seen with the addition of FPV, however the groups are not comparable and no adjustments were made. FPV was first used in patients whose clinical condition worsened or whose pneumonia findings progressed, while later patients started FPV treatment early.
Uçan et al., 4 Feb 2021, retrospective, Turkey, preprint, 8 authors, average treatment delay 4.73 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: Benefits of Treatment With Favipiravir in Hospitalized Patients for COVID-19: a Retrospective Observational Case-control Study Anıl Uçan (  ) Ministry of Health Pamir Çerçi Eskisehir State Hospital: Eskisehir Devlet Hastanesi Serdar Efe Eskisehir State Hospital: Eskisehir Devlet Hastanesi Hakan Akgün Eskişehir Devlet Hastanesi: Eskisehir Devlet Hastanesi Ahmet Özmen Eskişehir Devlet Hastanesi: Eskisehir Devlet Hastanesi Aysel Yağmuroğlu Eskişehir Devlet Hastanesi: Eskisehir Devlet Hastanesi Muzaffer Bilgin Osmangazi University: Eskisehir Osmangazi Universitesi Deniz Avcı Kayseri City Hospital: TC Saglik Bakanligi Kayseri Sehir Egitim ve Arastirma Hastanesi Research Keywords: Severe acute respiratory syndrome coronavirus 2, Pneumonia, Favipiravir, Hydroxychloroquine, Antiviral therapy Posted Date: February 4th, 2021 DOI: License:   This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/17 Abstract Background: Although more than a year past since COVID-19 was defined, there is no specific treatment yet. Since COVID-19 management differs over time, it is hard to determine which therapy is more efficacious. In this study, we aimed to evaluate the efficacy of the regimen with Favipiravir (FPV) and determine if the timing of FPV addition offers any improvement. Methods: A retrospective observational case-controlled cohort study was performed between March and Sep-tember 2020, including adults with COVID-19 in a single-center in Turkey. We categorized patients into age-sex matched three groups, group 1 (n=48) and group 2 (n=48) included patients treated with the combination of FPV plus Hydroxychloroquine (HQ) early and late, respectively. Group 3 (n=48) consisted of patients on HQ monot-herapy. In Group 2, if the respiratory or clinic condition had not improved sufficiently, FPV was added on or after day 3. Results: We found that starting FPV early had an impact on PCR negativity and the progression of the disease. 'No progression' was defined as the absence of a new finding in the control radiological examination and the absence of accompanying clinical deterioration. Also, the decrease in C-reactive protein (CRP) was greater in Group 1 than Group 3 (p <0.001). However, we found that early initiation of FPV treatment did not have a posi-tive effect on the estimated survival time. Conclusions: According to this retrospective study results, we believe that for better clinical outcomes, FPV treatment should be started promptly to enhance antiviral effects and improve clinical outcomes. Introductions The SARS-CoV-2 virus, most of its clinical manifestations causing a respiratory illness with noncharacteristic symptoms, was observed in a group of patients with unknown cause pneumonia in Wuhan, China, in December 2019 (1). By the time, the cause of this disease is understood to be a new coronavirus. It was temporarily named the new coronavirus 2019 (nCoV) by the World Health Organization (WHO). In February 2020, the emerging clinical manifestation was redefined as "COVID − 19" (coronavirus disease 2019). Since the beginning of the pandemic, the new coronavirus has caused over 79 million reported cases and more than 1.7 million deaths worldwide, as of December 29, 2020 (2). In COVID-19, there is an incubation period of approximately 5.2 days between the appearance of symptoms and..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop